Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial

• DOI: 10.1016/j.eng.2020.08.011
• Publication Date: 2020-09-08T02:48:30Z
• Authors: Xiaoke Wu; Kaijiang Yu; Yongchen Wang; Wanhai Xu; Hongli Ma; Yan Hou; Yue Li; Benzhi Cai; Liying Zhu; Min Zhang; Xiaoli Hu; Jingshu Gao; Yu Wang; Huichao Qin; Wenjie Wang; Mingyan Zhao; Xia Wu; Yong Zhang; Lu Li; Kang Li; Zhimin Du; Ben Willem J. Mol; Baofeng Yang
• Keywords: Concomitant; Clinical endpoint

No therapeutics have been proven effective yet for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2). To assess efficacy and safety Triazavirin therapy COVID-19, we conducted a randomized, double-blinded controlled trial involving hospitalized adult patients with COVID-19. Participants were enrolled from ten sites, randomized into two arms study ratio 1:1. Patients treated 250 mg versus placebo three or four times day 7 d. The primary outcome was set as time to clinical improvement, defined normalization body temperature, rate, oxygen saturation, cough, absorption pulmonary infection chest computed tomography (CT) until 28 d after randomization. Secondary outcomes included individual components outcome, mean proportion inflammatory in lung, conversion rate repeated negative SARS-CoV-2 nucleic acid test throat swab sampling. Concomitant therapeutic treatments, adverse events, serious events recorded. Our halted recruitment 52 patients, since number new infections participating hospitals decreased greatly. We (n = 26) 26). found no differences improvement (median, 12 d; risk (RR), 2.0; 95% confidence interval (CI), 0.7–5.6; p 0.2), occurring group six (38.5% 23.1%; RR, 2.1; CI, 0.6–7.0; 0.2). All normalized within d, exception (Triazavirin 50.0%, 26.1%). used less frequent concomitant therapies respiratory, cardiac, renal, hepatic, coagulation supports. Although statistically significant evidence indicate that benefits COVID-19 our observations indicated possible its use treat due antiviral effects. Further is required confirmation.